Peri-implantitis is one of the biggest threats to implant treatment. Depending on its severity, it can lead to loss of the implant, resulting in inconvenience for the patient and additional cost for the clinician. The Straumann® Tissue Level Implant outperformed competitive brands in a recent independent study performed on 427 patients out of a sample population of over 25,000 patient records obtained from the Swedish Social Insurance Agency.1